Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts. Show more
Location: 1560 Trapelo Road, Waltham, MA, 02451, United States | Website: https://www.dyne-tx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.088B
52 Wk Range
$6.36 - $47.45
Previous Close
$9.57
Open
$9.72
Volume
1,433,180
Day Range
$9.51 - $9.92
Enterprise Value
433.6M
Cash
677.5M
Avg Qtr Burn
-79.93M
Insider Ownership
0.69%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DYNE-101 Details Myotonic Dystrophy Type 1 | Phase 1/2 Data readout | |
Phase 1/2 Data readout |